Page 11 - Agent Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Japanese Corporate Venture Capital "CyberAgent Capital" Closes Latest Round of Fundraising Fetching over $55M News provided by Share this article Share this article TOKYO, May 20, 2021 /PRNewswire/ -- CyberAgent Capital, Inc., a member company of the Tokyo-based CyberAgent, Inc. group, has announced the closing of its "CA Startups Internet Fund 3rd," raising a total of 6 billion yen (US$55.5 million). CyberAgent Capital is a venture capital firm based across 8 countries and 10 cities, mainly in Asia, leading global innovation jointly with startups. Since its founding in 2006, the firm has bee...

Published: May 18, 2021 By Alex Keown Three companies on three separate continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.  Hummingbird Bioscience Raises $125 Million Singapore-based  raised $125 million in an oversubscribed Series C financing round. The funds will be used to support the development of the company’s two lead programs and advance its early-stage clinical research.  Hummingbird’s two lead assets are HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-...

MedCity News This week, read new developments at Carrum Health, Seven Bridges, CARISMA Therapeutics, and more. Shares0 Seven Bridges recently announced the formation of its strategic advisory board tasked with advising Seven Bridges leadership team in its mission to accelerate scientific discovery and speed the path from raw experimental data to new treatments and diagnostics. The appointment of three leaders with significant experience in healthcare and artificial intelligence will aid the company exploring new health-focused opportunities and bolster the company’s work with biopharmaceu...

4Bio Capital 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round 4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round Press Release 1 March 2021 LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced it has become an investor in CARISMA Therapeutics, a biopharmaceutical company focused on discovering and developing innovative immunotherapies. 4BIO participated in the second...

/PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the...